AnHeart Therapeutics

[Available On-Demand]
AnHeart Therapeutics is an oncology-focused clinical stage biopharmaceutical company headquartered in Hangzhou, China with offices in Beijing, Shanghai and New York. The company’s pipeline consists of three clinical stage assets: Taletrectinib, a next-gen ROS1 and NTRK inhibitor currently in Phase 2; an mIDH1 inhibitor ready for Phase 2 for low grade glioma, cholangiocarcinoma, AML and other tumors; and an AXL inhibitor in Phase 1 for overcoming resistance in various tumors.
Company Type:
Company HQ State:
Not Provided
Company HQ Country:
China
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
Taletrectinib
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
photo
Founder and CBO
AnHeart Therapeutics (Hangzhou) Co., Ltd.